Occurrence of Improper Accounting Treatment in Sales Transactions
First written in FY2016. 9 of 17 entries say "Materialised", first in FY2016. Latest entry: FY2021.
Techno Medica moved to the "Worse" side of this theme in 2016.
1 other company's latest entry also says "Mitigated".
- FY2021MitigatedAnnual report
「Extraordinary losses Loss on disposal of property, plant and equipment ¥0 Litigation-related costs - Total extraordinary losses ¥0」
No litigation-related costs or costs related to corrections to prior-year financial statements were recorded in the fiscal year, resulting in extraordinary losses related to the past improper accounting treatment of ¥0 for the current period. - FY2021-Q3RestatedAnnual report
「Extraordinary losses Litigation-related costs ¥10.553 million - Loss on disposal of property, plant and equipment ¥0.183 million ¥0 Total extraordinary losses ¥10.736 million ¥0」
Extraordinary losses were ¥0 in the cumulative third-quarter period, as litigation-related costs and other costs recorded in the same period of the prior year were not recorded in the current period. The reduced cost burden related to the past improper accounting treatment has continued. - FY2021-Q1MitigatedAnnual report
「Extraordinary losses Litigation-related costs ¥10.553 million - Total extraordinary losses ¥10.553 million -」
No litigation-related costs were recorded in the current quarter, and the amount of related costs recognized in the current period declined from ¥10.553 million recorded in the same period of the prior year. No cost burden related to the past improper accounting treatment was identified in the current quarter. - FY2020-Q2RestatedAnnual report
「Extraordinary income Compensation received - ¥80.000 million Total extraordinary income - ¥80.000 million Extraordinary losses Litigation-related costs - ¥10.553 million Loss on disposal of property, plant and equipment - ¥0.183 million Total extraordinary losses - ¥10.736 million」
While recording ¥80.000 million in compensation received as extraordinary income, the company continued to record ¥10.553 million in litigation-related costs. The recognition of legal costs related to the past improper accounting treatment has continued. - FY2020-Q1Continued recognition of litigation-related expensesAnnual report
「Extraordinary income Compensation received - ¥80.000 million Total extraordinary income - ¥80.000 million Extraordinary losses Litigation-related costs - ¥10.553 million Total extraordinary losses - ¥10.553 million」
During the cumulative first-quarter period, the company recorded ¥10.553 million in litigation-related costs, while recording ¥80.000 million in compensation received as extraordinary income. Recognition of legal costs related to the past improper accounting treatment has continued. - FY2019MitigatedAnnual report
「Extraordinary losses Costs related to corrections to prior-year financial statements - Litigation-related costs ¥2.152 million Total extraordinary losses ¥2.152 million」
No costs related to corrections to prior-year financial statements were recorded in the current period, and litigation-related costs were limited to ¥2.152 million. The amount recognized in the current period declined substantially from the prior period’s related costs of ¥56.038 million. - FY2019-Q3RestatedAnnual report
「Extraordinary losses Costs related to corrections to prior-year financial statements - Litigation-related costs ¥2.152 million Total extraordinary losses ¥2.152 million」
During the cumulative third-quarter period, no costs related to corrections to prior-year financial statements were recorded, and litigation-related costs remained limited to ¥2.152 million. The reduced level of related costs from the prior fiscal year has continued. - FY2019-Q2Reduction in current-period recognition of related costsAnnual report
「Extraordinary losses Costs related to corrections to prior-year financial statements - Litigation-related costs ¥2.152 million Total extraordinary losses ¥2.152 million」
During the cumulative second-quarter period, no costs related to corrections to prior-year financial statements were recorded, and litigation-related costs were limited to ¥2.152 million. The amount recognized in the current period in connection with the past improper accounting treatment declined from extraordinary losses of ¥45.246 million in the same period of the prior year. - FY2018MaterialisedAnnual report
「Extraordinary losses Costs related to corrections to prior-year financial statements ¥14.320 million Litigation-related costs ¥41.692 million Total extraordinary losses ¥56.038 million」
The company recorded ¥14.320 million in costs related to corrections to prior-year financial statements and ¥41.692 million in litigation-related costs, and the financial impact of the past improper accounting treatment continued to arise over the full fiscal year. - FY2018-Q3MaterialisedAnnual report
「Costs related to corrections to prior-year financial statements ¥14.320 million Litigation-related costs ¥31.692 million Total extraordinary losses ¥46.013 million」
The company recorded ¥14.320 million in costs related to corrections to prior-year financial statements and ¥31.692 million in litigation-related costs, and the financial impact of the past improper accounting treatment continued to arise in the third quarter. - FY2018-Q2MaterialisedAnnual report
「Costs related to corrections to prior-year financial statements ¥14.320 million Litigation-related costs ¥30.925 million Total extraordinary losses ¥45.246 million」
The company recorded ¥14.320 million in costs related to corrections to prior-year financial statements and ¥30.925 million in litigation-related costs, and the financial impact of the improper accounting treatment continued to arise in the second quarter. The impact was quantified again and is described as having actually occurred. - FY2018-Q1MaterialisedAnnual report
「Extraordinary losses Costs related to corrections to prior-year financial statements ¥14.320 million Litigation-related costs ¥12.350 million Total extraordinary losses ¥26.671 million」
The company recorded ¥14.320 million in costs related to corrections to prior-year financial statements and ¥12.350 million in litigation-related costs in the cumulative first-quarter period, and the financial impact of the past improper accounting treatment continues to arise. - FY2017MaterialisedAnnual report
「Net income for the fiscal year was ¥458.128 million, down 61.7% year on year, due to the recording of extraordinary losses consisting of the independent committee’s investigation costs related to the improper accounting treatment and various costs associated with corrections to prior-year financial statements.」
The company recorded ¥788.958 million in costs related to corrections to prior-year financial statements as an extraordinary loss. It also recorded an allowance for doubtful accounts of ¥171.944 million, equal to the long-term accounts receivable related to the misconduct, making the financial impact evident for the full fiscal year. - FY2017-Q3MaterialisedAnnual report
「Quarterly net income was ¥33.669 million, down 95.5% year on year, due to the recording of extraordinary losses consisting of the independent committee’s investigation costs related to the improper accounting treatment and various costs associated with corrections to prior-year financial statements.」
The company recorded ¥698.047 million in investigation and prior-year financial statement correction-related costs as an extraordinary loss, and the financial impact of the issue has become evident in the cumulative third-quarter period as well. - FY2017-Q2MaterialisedAnnual report
「During the cumulative second-quarter period, the company recorded investigation costs for the independent committee’s investigation into improper accounting treatment in prior years and various costs related to corrections to prior-year financial statements.」
The company recorded ¥658.107 million in costs related to corrections to prior-year financial statements as an extraordinary loss, and the financial impact of the improper accounting treatment has become evident in the current quarter as well. - FY2017-Q1MaterialisedAnnual report
「The company received on 23 June 2016 the results of an investigation by the independent committee into the appropriateness and validity of its past accounting treatment, and recorded the investigation costs in the cumulative first-quarter period. It plans to record, from the cumulative second-quarter period onward, various costs related to corrections to prior-year financial statements and other matters based on the investigation results, but the specific amount has not been determined at this time.」
The company received the independent committee’s investigation results and recorded investigation costs of ¥223.460 million as an extraordinary loss. Additional costs related to corrections to prior-year financial statements and other matters are expected, but the amount has not been determined. - FY2016MaterialisedAnnual report
「It has become clear, following comments from the accounting auditor and an investigation by the independent committee, that improper accounting treatment had been applied to the company’s sales transactions.」
The company states that improper accounting treatment in sales transactions was identified through the auditor’s comments and the independent committee’s investigation, leading to corrections to prior-year financial statements.